AstraZeneca's Truqap combination wins US approval as first targeted therapy for PTEN-deficient metastatic hormone-sensitive prostate cancer.
AstraZeneca announced that its combination therapy Truqap has been approved in the US as the first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
Open map near US
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
More story pages
Ebola spreading into new areas in northeast DR Congo, WHO warns
The World Health Organization reports that Ebola is spreading into new areas in northeast DR Congo.
WHO warns 'blind spots' may hide true scale of Congo's Ebola outbreak, suggesting cases could be higher than reported.
The World Health Organization has suggested that 'blind spots' in surveillance could obscure the full extent of the Ebola outbreak in the Democratic Republic of Congo.
Ebola outbreak reaches crowded displacement camp in eastern Congo, raising risk of rapid spread among vulnerable populations.
Ebola outbreak spreads to crowded displacement camp in Congo.
Florida oil trader shelves plan for largest US fuel shipment to Cuba since 1960 as Trump administration intensifies pressure on Havana.
A Florida oil trading house that was set to dispatch the largest US fuel shipment to Cuba since 1960 is shelving plans after the Trump administration ramps up pressure on the island.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.